Pharmacogenetic Landscape of DPYD Variants in South Asian Populations by Integration of Genome-Scale Data
- 14 December 2017
- journal article
- research article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 19 (3) , 227-241
Abstract
Adverse drug reactions to 5-Fluorouracil(5-FU) is frequent and largely attributable to genetic variations in the DPYD gene, a rate limiting enzyme that clears 5-FU. The study aims at understanding the pharmacogenetic landscape of DPYD variants in south Asian populations. Systematic analysis of population scale genome wide datasets of over 3000 south Asians was performed. Independent evaluation was performed in a small cohort of patients. Our analysis revealed significant differences in the the allelic distribution of variants in different ethnicities. This is the first and largest genetic map the DPYD variants associated with adverse drug reaction to 5-FU in south Asian population. Our study highlights ethnic differences in allelic frequencies.Keywords
Funding Information
- Council of Scientific and Industrial Research ((BSC0212))
- INDICO ((BSC0122))
- The data for pharmacogenetic variants ((MLP1601))
This publication has 49 references indexed in Scilit:
- Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracilCell Death & Disease, 2013
- Genome-Wide Association Study for Type 2 Diabetes in Indians Identifies a New Susceptibility Locus at 2q21Diabetes, 2013
- SIFT web server: predicting effects of amino acid substitutions on proteinsNucleic Acids Research, 2012
- Genotype Frequencies of Drug-Metabolizing Enzymes Responsible for Purine and Pyrimidine Antagonists in a Healthy Asian-Indian PopulationBiochemical Genetics, 2012
- INDICO: the development of a resource for epigenomic study of Indians undergoing socioeconomic transitionThe HUGO Journal, 2011
- 5-FU Metabolism in Cancer and Orally-Administrable 5-FU DrugsCancers, 2010
- A method and server for predicting damaging missense mutationsNature Methods, 2010
- A well‐tolerated 5‐FU‐based treatment subsequent to severe capecitabine‐induced toxicity in a DPD‐deficient patientBritish Journal of Clinical Pharmacology, 2008
- The International HapMap ProjectNature, 2003
- Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?European Journal of Cancer, 2000